Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The investigators reported that the treatment has been well tolerated to date, and that 19 of 44 evaluable patients experienced stable disease ranging from two to 20 months, resulting in a total clinical benefit rate (complete response + partial response + stable disease) of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (greater than 6 months) or better, for the agent to be considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed following surgery, while the other has Ewing's Sarcoma and had previously progressed following multiple treatments.

"We were very happy to participate in the study," said Dr. Mita. "REOLYSIN is a promising option for patients with sarcoma as shown by the results of this study. As a single agent the virus had a clinical benefit rate of 43% and it was very well tolerated. Further studies combining REOLYSIN with chemotherapy are contempl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed outperformed 137 ... Summit in San Francisco to take first place in ... Valley investors and technology elites as the premier showcase ... Briteseed to move on to the final phase ... with other elite innovation finalists for a $125,000 cash ...
(Date:11/22/2014)... November 22, 2014 Respiratory therapy ... the proper management of life-like respiratory ailments using ... devices . Grand Rapids-based, Michigan Instruments Inc. developers ... two of the respiratory simulation units to the ... Grand Valley and Muskegon Community College are collaborating ...
(Date:11/22/2014)... 2014   , ... Officer zu KLOX    ... Financial Officer bestellt    KLOX ist ... jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)...   TRU-D SmartUVC LLC and its UK partners, ... disinfection robot, TRU-D SmartUVC, at FIS 2014 in ... 26 at Stand 23. The conference, hosted by ... largest infection-related event of its kind and brings ... the leading events of its type throughout the world. This ...
Breaking Biology Technology:Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3
... N.J., July 31 Genta,Incorporated (OTC Bulletin Board: ... second quarter 2008 financial results on Thursday, August,7, ... and live audio,webcast to discuss these financial results ... can access the live call by dialing (877) ...
... Corporation,(Nasdaq: ALUS ), the worldwide leader in ... today,announced that it will hold a conference call ... a corporate update. Bill Worthen,president and CEO, will ... Time,(4:30 p.m. Eastern Time) on Thursday, August 7. ...
... a,global provider of products and services that improve ... a three-year agreement with,Prime Therapeutics, one of the ... primary supply chain partner for branded and generic,pharmaceuticals, ... than $8.2 billion in prescription drug,spend in 2007, ...
Cached Biology Technology:Genta Announces Second Quarter 2008 Financial Results and Conference Call 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 3Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 2Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement 2
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the ... phase. In its first six months of existence, the Lab ... evidence support for local law enforcement. "Because our ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... the possible inventory of molecules available to the ... research professor at Arizona State University, found that ... blazing fireball over California last year, contains organic ... findings suggest a far greater availability of extraterrestrial ...
... of Pharmaceutical Scientists (AAPS) WHAT: ... share the latest groundbreaking scientific discoveries and industry developments ... event will bring together more than 8,000 scientists, business ... initiatives underway aimed at improving global health through advances ...
... have discovered a new defense mechanism that the immune ... how a novel protein unexpectedly activates an immune response ... get rid of tumour cells. This research was done ... July 2013 in Nature Immunology ., 2. The immune ...
Cached Biology News:ASU scientists strike scientific gold with meteorite 2Novel mechanism discovered in first line of immune defense 2
... contains a precipitant to ensure that the samples ... to allow the user to follow the progress ... ABgene ® s proprietary mixture of red ... composition used in ReddyRun™ molecular weight markers. It ...
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,381-3) ...
MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
Biology Products: